Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2022 07:44 ET | Source: Athenex, Inc.

Athenex 提供 2021 年第四季度及該年全年度財務業績並提供業務更新

宣佈以細胞療法計劃為焦點的策略重心新藥臨床試驗 (IND) 獲得美國食品藥物管理局批准，將 CD19 CAR-NKT ANCHOR 擴展到多中心研究以實現顯著的成本削減計劃，目標是減少 50% 以上的營運經費計劃在 2022 年透過跟焦點與策略轉變一致的非核心資產營利來擴展其現金流管理層將主持會議通話和網絡廣播，時間為今天下午 4:30 （美國東部時間）舉行紐約州水牛城,...
March 16, 2022 16:10 ET | Source: Athenex, Inc.

Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Announces Strategic Pivot to Focus on Cell Therapy Programs Receives FDA Clearance for IND to Expand CD19 CAR-NKT ANCHOR to a Multi-center Study Implementing Significant Cost Reduction Plan...
March 14, 2022 08:00 ET | Source: Athenex, Inc.

更正：Athenex 將在 2022 年 3 月 16 日為 2021 年第四季度及該年全年度提供企業及財務更新

紐約水牛城, March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司。今天宣佈將在 2022 年 3 月 16 日（星期三）發表 2021 年第四季度及該年全年度的企業及財務更新。Athenex 的管理團隊將於下午 4:30...
March 14, 2022 08:00 ET | Source: Athenex, Inc.

CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022

BUFFALO, N.Y., March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the...
March 07, 2022 08:00 ET | Source: Athenex, Inc.

Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022

BUFFALO, N.Y., March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the...
March 07, 2022 08:00 ET | Source: Athenex, Inc.

Athenex 將在 2022 年 3 月 15 日為 2021 年第四季度及該年全年度提供企業及財務更新

紐約水牛城, March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司。今天宣佈將在 2022 年 3 月 15 日（星期二）的市場開放前，發表 2021 年第四季度及該年全年度的企業及財務更新。Athenex 的管理團隊將於上午 8:00...
February 22, 2022 08:00 ET | Source: Athenex, Inc.

Athenex 宣佈委任財務總監

紐約水牛城, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc.(NASDAQ: ATNX) 是一家致力於研究、開發及將治療癌症與相關疾病新療法商業化的全球生物製藥公司，今天宣佈 Joe Annoni 先生將加入 Athenex 擔任新的財務總監兼公司行政官，且即時生效。 Annoni 先生是一位成功的金融專業人士，並在私募股權、投資銀行和...
February 22, 2022 08:00 ET | Source: Athenex, Inc.

Athenex Announces Appointment of Chief Financial Officer

BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
February 15, 2022 09:00 ET | Source: Athenex, Inc.

Athenex 宣佈完成出售 Dunkirk 製造工廠

紐約水牛城, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 是一家全球生物製藥公司，致力研發現、開發及將治療癌症及相關疾病的新治療方法商品化，今天宣佈以約 4,000 萬美元的價格將其在紐約鄧寇克的製造工廠的租賃權益出售給 ImmunityBio, Inc. (NASDAQ: IBRX)。 ...
February 15, 2022 09:00 ET | Source: Athenex, Inc.

Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility

BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...